



NEW STUDY PROJECTS DEVASTATING LOSSES TO DRUG DEVELOPMENT, JOBS AND PATIENT HEALTH IN BIOPHARMA ECOSYSTEM

PROPOSED GOVERNMENT-MANDATED DRUG PRICING POLICIES AMOUNT TO 237 FEWER FDA APPROVALS AND 1.1M LOST JOBS OVER THE NEXT 10 YEARS

A new study estimates that there would be lost therapies for patients battling cancer, neurological, and rare and infectious diseases if Congress enacts new aggressive government-mandated drug pricing policies. Research firm Vital Transformation modeled the impacts of expanded government-mandated drug pricing policies, and analyzed the reduction of new drug approvals and loss of jobs if these policies or others similar to them would be enacted into law.



KEY STUDY HIGHLIGHTS:

The study found that, if the proposed IRA expansion is implemented, there are serious consequences around the development of and investment in new medicines, and significant job losses in major innovation hubs across a number of states.

LOST THERAPIES



More than **80** currently available therapies of **121** identified for price setting – approximately **70%** – would likely have not been developed had the pricing provisions been in place prior to their development.

LOST INNOVATION



There would be **237** fewer FDA approvals of new medicines or new uses over a **10-year** period. Impacts of the proposed policies will be felt most heavily in many areas of unmet need, including in oncology, neurology, and rare and infectious diseases.

LOST JOBS & INVESTMENT



This would result in a loss of **146,000-223,000** direct biopharmaceutical industry jobs and a total loss of **730,000-1,100,000** U.S. jobs across the economy. There would be loss of ecosystem investments into **50** different therapeutic indications, concentrated primarily in California, Massachusetts and New York.

The study modeled the impacts on industry revenues and future R&D investments and estimated future lost innovation impacts, including the impact on industry jobs. The analysis was performed by Vital Transformation's consulting economist Dr. Harry Bowen, research partner Dr. Daniel Gassull and CEO Duane Schulthess. See the study [here](#).